AB1077 The spread of tophaceous disease strongly predicts time to new flare in gouty arthritis

AB1077 The spread of tophaceous disease strongly predicts time to new flare in gouty arthritis

Background In gouty arthritis (GA) elevated serum urate (SU) levels lead to the monosodium urate (MSU) crystal deposition (tophi) in cartilage, tendon sheaths, and subcutaneous tissue. This usually appears late in the disease course and indicates disease severity. However, currently there is no quan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2013-06, Vol.71 (Suppl 3), p.699-699
Hauptverfasser: Schlesinger, N., Sunkureddi, P., Alten, R., Bardin, T., Shpilsky, A., Kiechle, T., So, A.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 699
container_issue Suppl 3
container_start_page 699
container_title Annals of the rheumatic diseases
container_volume 71
creator Schlesinger, N.
Sunkureddi, P.
Alten, R.
Bardin, T.
Shpilsky, A.
Kiechle, T.
So, A.
description Background In gouty arthritis (GA) elevated serum urate (SU) levels lead to the monosodium urate (MSU) crystal deposition (tophi) in cartilage, tendon sheaths, and subcutaneous tissue. This usually appears late in the disease course and indicates disease severity. However, currently there is no quantitative measure to differentiate severe from less severe GA patients using spread of tophaceous disease. Objectives To develop a quantitative measure of GA severity by the number of tophi locations. Methods Pooled analysis of two 12-week studies (β-RELIEVED, N=230; β-RELIEVED II, N=226) followed by 12-week extensions, demonstrated a significant reduction in time to new flare in patients treated with canakinumab 150 mg s.c. vs. triamcinolone acetonide (TA) 40 mg i.m. (p
doi_str_mv 10.1136/annrheumdis-2012-eular.1076
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777976442</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008663161</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1652-141a7f0153c6831406b52873c150712c915a9ead4e1ae881d848687c71778fb83</originalsourceid><addsrcrecordid>eNqVkMtOwzAQRS0EEqXwD5a6DnjysB2xKhUUUFWQKLA0TuI0Kc0D2xF0x4Yf5UtwCUJsWVm2z507OgiNgBwDBPRE1rUuVFdlpfF8Ar6nurXUx0AY3UEDCCl3z5TsogEhJPDCmLJ9dGDMyl0JBz5AT-MzR7PP949FobBptZIZbnJsm7aQqWo6g91wJY37tLqpl-sNdlBWptZgW1bKkbhWrzh3xQqXNV42nd1gqW2hS1uaQ7SXy7VRRz_nEN1fnC8ml97sZno1Gc-8BGjkexCCZDmBKEgpDyAkNIl8zoIUIsLAT2OIZOx2CxVIxTlkPOSUs5QBYzxPeDBEo35uq5uXThkrVk2na1cpHMJiRsPQd9RpT6W6MUarXLS6rKTeCCBiq1T8USq2SsW3UrFV6tJeny6NVW-_UamfBWUBi8T8YSIe76az6_ktiKnjac8n1epfRV86bJFr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777976442</pqid></control><display><type>article</type><title>AB1077 The spread of tophaceous disease strongly predicts time to new flare in gouty arthritis</title><source>BMJ Journals - NESLi2</source><creator>Schlesinger, N. ; Sunkureddi, P. ; Alten, R. ; Bardin, T. ; Shpilsky, A. ; Kiechle, T. ; So, A.</creator><creatorcontrib>Schlesinger, N. ; Sunkureddi, P. ; Alten, R. ; Bardin, T. ; Shpilsky, A. ; Kiechle, T. ; So, A.</creatorcontrib><description>Background In gouty arthritis (GA) elevated serum urate (SU) levels lead to the monosodium urate (MSU) crystal deposition (tophi) in cartilage, tendon sheaths, and subcutaneous tissue. This usually appears late in the disease course and indicates disease severity. However, currently there is no quantitative measure to differentiate severe from less severe GA patients using spread of tophaceous disease. Objectives To develop a quantitative measure of GA severity by the number of tophi locations. Methods Pooled analysis of two 12-week studies (β-RELIEVED, N=230; β-RELIEVED II, N=226) followed by 12-week extensions, demonstrated a significant reduction in time to new flare in patients treated with canakinumab 150 mg s.c. vs. triamcinolone acetonide (TA) 40 mg i.m. (p&lt;0.0001). Additional retrospective analysis was conducted to explore the impact of the spread of tophaceous disease on time to new flare. A new quantitative measure was derived by summation of tophi locations (right upper limb, left upper limb, right lower limb, left lower limb, and one “other”) resulting in a 6-point ordinal measurement scale. Number of tophi locations, using this scale, ranged from 0 to 5. The number of tophi locations was evaluated as a covariate in the Cox regression model using Wald Chi-Square test. Results The number of tophi locations revealed a high statistical significance along with treatment effect (p&lt;0.0001 for both) i.e. the fewer the number of tophi locations, the longer the time to new flare. A similar result was obtained from Kaplan-Meier (K-M) analysis using log-rank test across the strata of 3 subgroups of tophi category (0, 1-2, 3-5) [Figure]. Conclusions Our results suggest that the number of locations to which tophaceous formations have spread throughout the body leading to systemic disease is an indicator of disease severity in GA. This quantitative measure is a strong predictor of delay of new flare (the higher the number of locations the less delay in reflares). Disclosure of Interest N. Schlesinger Grant/Research support from: Novartis, Consultant for: Novartis,URL Pharma, Savient, Takeda, Rx Ensyme, Speakers Bureau: Novartis, P. Sunkureddi Consultant for: Novartis, Bristol Myers Squibb, UCB, Pfizer, Speakers Bureau: Novartis, Bristol Myers Squibb, UCB, Pfizer, R. Alten Grant/Research support from: Novartis, Consultant for: Novartis, Speakers Bureau: Novartis, T. Bardin Grant/Research support from: Menarini, Consultant for: Novartis, Ipsen, Menarini, Ardea, Biocryst, Speakers Bureau: Novartis, A. Shpilsky Shareholder of: Novartis, Employee of: Novartis, T. Kiechle Shareholder of: Novartis, Employee of: Novartis, A. So Grant/Research support from: Novartis, Consultant for: Novartis, Ardea, Speakers Bureau: Novartis, Ardea, Menarini</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2012-eular.1076</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><ispartof>Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.699-699</ispartof><rights>2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/71/Suppl_3/699.16.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/71/Suppl_3/699.16.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,315,781,785,3197,23573,27926,27927,77602,77633</link.rule.ids></links><search><creatorcontrib>Schlesinger, N.</creatorcontrib><creatorcontrib>Sunkureddi, P.</creatorcontrib><creatorcontrib>Alten, R.</creatorcontrib><creatorcontrib>Bardin, T.</creatorcontrib><creatorcontrib>Shpilsky, A.</creatorcontrib><creatorcontrib>Kiechle, T.</creatorcontrib><creatorcontrib>So, A.</creatorcontrib><title>AB1077 The spread of tophaceous disease strongly predicts time to new flare in gouty arthritis</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Background In gouty arthritis (GA) elevated serum urate (SU) levels lead to the monosodium urate (MSU) crystal deposition (tophi) in cartilage, tendon sheaths, and subcutaneous tissue. This usually appears late in the disease course and indicates disease severity. However, currently there is no quantitative measure to differentiate severe from less severe GA patients using spread of tophaceous disease. Objectives To develop a quantitative measure of GA severity by the number of tophi locations. Methods Pooled analysis of two 12-week studies (β-RELIEVED, N=230; β-RELIEVED II, N=226) followed by 12-week extensions, demonstrated a significant reduction in time to new flare in patients treated with canakinumab 150 mg s.c. vs. triamcinolone acetonide (TA) 40 mg i.m. (p&lt;0.0001). Additional retrospective analysis was conducted to explore the impact of the spread of tophaceous disease on time to new flare. A new quantitative measure was derived by summation of tophi locations (right upper limb, left upper limb, right lower limb, left lower limb, and one “other”) resulting in a 6-point ordinal measurement scale. Number of tophi locations, using this scale, ranged from 0 to 5. The number of tophi locations was evaluated as a covariate in the Cox regression model using Wald Chi-Square test. Results The number of tophi locations revealed a high statistical significance along with treatment effect (p&lt;0.0001 for both) i.e. the fewer the number of tophi locations, the longer the time to new flare. A similar result was obtained from Kaplan-Meier (K-M) analysis using log-rank test across the strata of 3 subgroups of tophi category (0, 1-2, 3-5) [Figure]. Conclusions Our results suggest that the number of locations to which tophaceous formations have spread throughout the body leading to systemic disease is an indicator of disease severity in GA. This quantitative measure is a strong predictor of delay of new flare (the higher the number of locations the less delay in reflares). Disclosure of Interest N. Schlesinger Grant/Research support from: Novartis, Consultant for: Novartis,URL Pharma, Savient, Takeda, Rx Ensyme, Speakers Bureau: Novartis, P. Sunkureddi Consultant for: Novartis, Bristol Myers Squibb, UCB, Pfizer, Speakers Bureau: Novartis, Bristol Myers Squibb, UCB, Pfizer, R. Alten Grant/Research support from: Novartis, Consultant for: Novartis, Speakers Bureau: Novartis, T. Bardin Grant/Research support from: Menarini, Consultant for: Novartis, Ipsen, Menarini, Ardea, Biocryst, Speakers Bureau: Novartis, A. Shpilsky Shareholder of: Novartis, Employee of: Novartis, T. Kiechle Shareholder of: Novartis, Employee of: Novartis, A. So Grant/Research support from: Novartis, Consultant for: Novartis, Ardea, Speakers Bureau: Novartis, Ardea, Menarini</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkMtOwzAQRS0EEqXwD5a6DnjysB2xKhUUUFWQKLA0TuI0Kc0D2xF0x4Yf5UtwCUJsWVm2z507OgiNgBwDBPRE1rUuVFdlpfF8Ar6nurXUx0AY3UEDCCl3z5TsogEhJPDCmLJ9dGDMyl0JBz5AT-MzR7PP949FobBptZIZbnJsm7aQqWo6g91wJY37tLqpl-sNdlBWptZgW1bKkbhWrzh3xQqXNV42nd1gqW2hS1uaQ7SXy7VRRz_nEN1fnC8ml97sZno1Gc-8BGjkexCCZDmBKEgpDyAkNIl8zoIUIsLAT2OIZOx2CxVIxTlkPOSUs5QBYzxPeDBEo35uq5uXThkrVk2na1cpHMJiRsPQd9RpT6W6MUarXLS6rKTeCCBiq1T8USq2SsW3UrFV6tJeny6NVW-_UamfBWUBi8T8YSIe76az6_ktiKnjac8n1epfRV86bJFr</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Schlesinger, N.</creator><creator>Sunkureddi, P.</creator><creator>Alten, R.</creator><creator>Bardin, T.</creator><creator>Shpilsky, A.</creator><creator>Kiechle, T.</creator><creator>So, A.</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201306</creationdate><title>AB1077 The spread of tophaceous disease strongly predicts time to new flare in gouty arthritis</title><author>Schlesinger, N. ; Sunkureddi, P. ; Alten, R. ; Bardin, T. ; Shpilsky, A. ; Kiechle, T. ; So, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1652-141a7f0153c6831406b52873c150712c915a9ead4e1ae881d848687c71778fb83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schlesinger, N.</creatorcontrib><creatorcontrib>Sunkureddi, P.</creatorcontrib><creatorcontrib>Alten, R.</creatorcontrib><creatorcontrib>Bardin, T.</creatorcontrib><creatorcontrib>Shpilsky, A.</creatorcontrib><creatorcontrib>Kiechle, T.</creatorcontrib><creatorcontrib>So, A.</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schlesinger, N.</au><au>Sunkureddi, P.</au><au>Alten, R.</au><au>Bardin, T.</au><au>Shpilsky, A.</au><au>Kiechle, T.</au><au>So, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB1077 The spread of tophaceous disease strongly predicts time to new flare in gouty arthritis</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2013-06</date><risdate>2013</risdate><volume>71</volume><issue>Suppl 3</issue><spage>699</spage><epage>699</epage><pages>699-699</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background In gouty arthritis (GA) elevated serum urate (SU) levels lead to the monosodium urate (MSU) crystal deposition (tophi) in cartilage, tendon sheaths, and subcutaneous tissue. This usually appears late in the disease course and indicates disease severity. However, currently there is no quantitative measure to differentiate severe from less severe GA patients using spread of tophaceous disease. Objectives To develop a quantitative measure of GA severity by the number of tophi locations. Methods Pooled analysis of two 12-week studies (β-RELIEVED, N=230; β-RELIEVED II, N=226) followed by 12-week extensions, demonstrated a significant reduction in time to new flare in patients treated with canakinumab 150 mg s.c. vs. triamcinolone acetonide (TA) 40 mg i.m. (p&lt;0.0001). Additional retrospective analysis was conducted to explore the impact of the spread of tophaceous disease on time to new flare. A new quantitative measure was derived by summation of tophi locations (right upper limb, left upper limb, right lower limb, left lower limb, and one “other”) resulting in a 6-point ordinal measurement scale. Number of tophi locations, using this scale, ranged from 0 to 5. The number of tophi locations was evaluated as a covariate in the Cox regression model using Wald Chi-Square test. Results The number of tophi locations revealed a high statistical significance along with treatment effect (p&lt;0.0001 for both) i.e. the fewer the number of tophi locations, the longer the time to new flare. A similar result was obtained from Kaplan-Meier (K-M) analysis using log-rank test across the strata of 3 subgroups of tophi category (0, 1-2, 3-5) [Figure]. Conclusions Our results suggest that the number of locations to which tophaceous formations have spread throughout the body leading to systemic disease is an indicator of disease severity in GA. This quantitative measure is a strong predictor of delay of new flare (the higher the number of locations the less delay in reflares). Disclosure of Interest N. Schlesinger Grant/Research support from: Novartis, Consultant for: Novartis,URL Pharma, Savient, Takeda, Rx Ensyme, Speakers Bureau: Novartis, P. Sunkureddi Consultant for: Novartis, Bristol Myers Squibb, UCB, Pfizer, Speakers Bureau: Novartis, Bristol Myers Squibb, UCB, Pfizer, R. Alten Grant/Research support from: Novartis, Consultant for: Novartis, Speakers Bureau: Novartis, T. Bardin Grant/Research support from: Menarini, Consultant for: Novartis, Ipsen, Menarini, Ardea, Biocryst, Speakers Bureau: Novartis, A. Shpilsky Shareholder of: Novartis, Employee of: Novartis, T. Kiechle Shareholder of: Novartis, Employee of: Novartis, A. So Grant/Research support from: Novartis, Consultant for: Novartis, Ardea, Speakers Bureau: Novartis, Ardea, Menarini</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><doi>10.1136/annrheumdis-2012-eular.1076</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.699-699
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1777976442
source BMJ Journals - NESLi2
title AB1077 The spread of tophaceous disease strongly predicts time to new flare in gouty arthritis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T09%3A29%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB1077%E2%80%85The%20spread%20of%20tophaceous%20disease%20strongly%20predicts%20time%20to%20new%20flare%20in%20gouty%20arthritis&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Schlesinger,%20N.&rft.date=2013-06&rft.volume=71&rft.issue=Suppl%203&rft.spage=699&rft.epage=699&rft.pages=699-699&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2012-eular.1076&rft_dat=%3Cproquest_cross%3E4008663161%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777976442&rft_id=info:pmid/&rfr_iscdi=true